NEW YORK (GenomeWeb News) – Qiagen announced after the close of the market on Thursday that it has exclusively licensed a biomarker that it plans to use in a molecular diagnostic test for a group of blood disorders called myeloproliferative neoplasms.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.